Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 15, 2007 Brian Orelli	Slowing the Cash Burn Bloody Nose Nastech plans to cut costs following Proctor& Gamble's drop of their osteoporosis drug. Investors, take note.
The Motley Fool October 31, 2007 Brian Lawler	Nastech Still Breathing Coming phase 2 results on four different compounds will help investors assess how well Nastech's nasally-administered drugs might sell. Investors, take note.
The Motley Fool May 16, 2007 Mike Havrilla	Nastech Nose Potential The small biotech reports the achievement of positive results for carbetocin nasal spray for the treatment of autism symptoms along with the completion of a $41 million stock offering in January.
The Motley Fool July 14, 2006 Stephen D. Simpson	FDA Bloodies Nastech's Nose An FDA rejection for a generic drug is a setback, but not a major one. Experienced biotech investors realize that ideas like Nastech are often binary outcomes -- it's either going to be a big winner or a total flop.
The Motley Fool June 17, 2004 Seth Jayson	P&G Patches Up Sex Life? Proctor & Gamble announced that a second phase 3 clinical trial had demonstrated the safety and efficacy of its testosterone patch, to be called Intrinsa, for treating sexual dysfunction in women.
The Motley Fool September 28, 2004 Brian Gorman	Fat Profits? Nastech makes a deal with Merck to develop an obesity drug.
The Motley Fool January 7, 2011 Brian Orelli	A Biotech Roller Coaster Lexicon is back on the upswing.
The Motley Fool August 19, 2009 Brian Orelli	Them's the Breaks for Lilly The drugmaker cuts its losses after a disappointing trial on an osteoporosis drug.
The Motley Fool January 31, 2011 Andrew Bond	A Consumer Giant That's on the Cutting Edge Procter & Gamble's innovation comes from many sources.
The Motley Fool November 1, 2005 Nathan Parmelee	A Small Surprise From P&G Proctor & Gamble delivers, just like it promised, releasing first-quarter earnings that were actually a penny ahead of expectations.
The Motley Fool October 1, 2009 Robert Steyer	For Drugmakers, It's All In or Get Out The Solvay-Abbott deal illustrates why conglomerates are getting out of the prescription-drug business.
The Motley Fool November 9, 2006 Todd Wenning	The Best Blue Chip for 2007: Procter & Gamble Investors, this omnipotent consumer staples firm is the best blue chip in the market.
The Motley Fool April 13, 2006 John Reeves	A Foolish Baby Shower: Procter & Gamble Few stocks have performed as well over the long term as Procter & Gamble. Clearly, this company is built to last. Investors, take note.
The Motley Fool August 25, 2009 Mike Pienciak	Will P&G Ever Turn Around? Will the recently announced sale of its pharmaceutical business to specialty-drugs developer Warner Chilcott mark a turning point for Proctor & Gamble, or just another misstep?
The Motley Fool January 26, 2006 Rich Smith	Foolish Forecast: Procter & Gamble Lathers Up If P&G continues to highlight the Household Care and Beauty businesses from the home team, and the Blades & Razors and Duracell & Braun divisions from Gillette as its star players, wise investors should give this stock a glance.
The Motley Fool January 27, 2006 Stephen D. Simpson	P&G Stocks Up on Profits Solid execution continues to be the hallmark of this consumer-goods giant. Investors, take note.
The Motley Fool October 26, 2010 Matt Koppenheffer	Can Procter & Gamble Defeat the Private Labels? Can P&G's latest marketing push help it reinvigorate sales in its largest market?
CIO August 24, 2009 Rick Swanborg	How Procter & Gamble Got Employees to Use Social Networking at Work Procter & Gamble drove adoption of social networking tools by integrating them with existing work processes.
The Motley Fool July 16, 2010 Sean Sun	Stock Cheat Sheet: Procter & Gamble If you're new to Procter & Gamble, consider this your cheat sheet to get introduced to the consumer products giant.
The Motley Fool February 27, 2008 Colleen Paulson	Making the Tough Decisions Delivering double-digit toothpaste and soap growth means that Procter & Gamble must be meticulous about cost control, and P&G has signaled once again that it will proactively manage its business to success.
The Motley Fool June 13, 2008 Brian Lawler	Lilly Patches Its Pipeline An early-stage compound joins the pharmaceutical's upcoming roster.
The Motley Fool August 6, 2009 Colleen Paulson	Procter & Gamble Fights the Tide Global currency fluctuations and declining volume hurt P&G's profits in the fourth quarter.
The Motley Fool October 27, 2004 Alyce Lomax	P&G Plows Along Investors got the jitters today, but Procter & Gamble's still strong.
The Motley Fool October 30, 2009 Mike Pienciak	P&G Inches Forward Slowly, very slowly, Procter & Gamble is crawling out of consumer-staples purgatory. But don't be fooled -- the world's largest consumer products company has a long way to go before it reaches growth nirvana.
The Motley Fool April 30, 2010 Mike Pienciak	P&G Pays the Price for Growth Product discounting and increased ad spending held back profit growth at Proctor & Gamble.
The Motley Fool January 28, 2011 Matt Koppenheffer	Procter & Gamble Shareholders Need Some Cheer Shares of Procter & Gamble take a dip after it announced fourth-quarter results.
The Motley Fool August 31, 2010 Matt Koppenheffer	How Much Is Procter & Gamble Worth? Is Procter & Gamble's stock on sale?
BusinessWeek July 12, 2004	At P&G, It's All About Targeting Consumer-product giant Procter & Gamble's global marketing officer explains why its ability to "embrace" the new diversity of media "is really exciting"
The Motley Fool June 27, 2008 Alex Dumortier	Recession-Proof Stocks: Procter & Gamble Do you use a disposable razor? Do you brush your teeth? If so, there's a three-out-of-four chance you use one of Proctor & Gamble's products, and you will continue to do so even if the country goes into recession.
The Motley Fool January 11, 2010 Mike Pienciak	Is P&G Overextending Itself? Recession-smacked Procter & Gamble may not be making all the right moves these days, but it certainly isn't sitting still, either.
The Motley Fool January 30, 2009 Colleen Paulson	It's a Big World, P&G Global currency fluctuations eat into Procter & Gamble's quarterly earnings.
The Motley Fool August 6, 2008 Timothy M. Otte	A Triple-Play Stock Consumer products giant Proctor & Gamble posts impressive fourth-quarter results.
The Motley Fool August 4, 2010 Matt Koppenheffer	Have You Sold Your Procter & Gamble Shares Yet? Procter & Gamble reported earnings that disappointed the market.
The Motley Fool August 3, 2006 Steven Mallas	A Prosperous P&G Procter & Gamble had a great year that was aided by the Gillette acquisition. This equity is a great long-term core holding; if you see it at an even higher yield, do yourself a favor and take a hard look at this stalwart operation.
The Motley Fool January 22, 2010 Mike Pienciak	Can P&G Be the Amazon.com of Consumer Staples? Management hopes a new online store will boosts sales and provide consumer insight.
The Motley Fool July 19, 2010 Eric Bleeker	Procter & Gamble's Tricky Ambitions Can it maintain margins while moving further into value segments?
The Motley Fool April 1, 2004 Bill Mann	P&G Unloads Sunny D Procter & Gamble sells its juice-based drink brand to J.W. Childs.
The Motley Fool January 31, 2007 Steven Mallas	P&G Still Lets You Sleep at Night Procter & Gamble delivered its second-quarter results yesterday. The market didn't seem impressed; its shares traded slightly to the downside. Is there something wrong with P&G?
The Motley Fool December 28, 2006 Michael Leibert	Fool on the Street: P&G Still Going Strong Investors who believe that the consumer goods giant can achieve organic sales growth of 4% to 7% over the next few years might consider the current share price to be an attractive entry point to own a stake in an industry leader.
BusinessWeek October 4, 2004 Berner et al.	P&G Has Rivals In A Wringer Colgate and Unilever are hurting as Proctor & Gamble rolls out creative products and marketing.
The Motley Fool October 12, 2005 Steven Mallas	P&G Gambles on Prosperity Shareholders will have a nice stock on their hands for a while. Procter & Gamble sees steady growth four years out.
The Motley Fool May 5, 2006 Tim Beyers	Wall Street Gets One Right Procter & Gamble's big sales and earnings gains aren't enough for investors.
The Motley Fool August 3, 2007 Ryan Fuhrmann	Procter & Gamble Leads the Way In its fourth-quarter and full-year earnings conference call, Proctor & Gamble shows why it continues to dominate the global market in consumer goods.
BusinessWeek July 25, 2005 Robert Barker	P&G's $57 Billion Bargain Should it close, Procter & Gamble's $57 billion deal for Gillette is likely to stand as this year's biggest. Focusing on three different sets of numbers, for investors P&G stock looks like a bargain.
The Motley Fool June 3, 2010 Jim Royal	1 Reason Procter & Gamble Is a Must-Have It's a boring -- but safe -- company.
BusinessWeek June 21, 2004 Catherine Arnst	Guard Your Bones Osteoporosis is one of the biggest health risks facing older women. What can be done to help prevent this disease?
The Motley Fool May 12, 2004 Brian Gorman	Procter & Gamble Bets on China The consumer products powerhouse looks like it's making all the right moves.
The Motley Fool October 29, 2008 Colleen Paulson	This Stock Isn't a Gamble Good old Procter & Gamble produced its usual respectable first-quarter earnings, highlighted by 9% revenue growth and 12% EPS gains in the wake of rising commodity costs.
The Motley Fool February 4, 2008 Timothy M. Otte	Predictable Procter & Gamble Investors can find comfort in solid, predictable results like those from Procter & Gamble's second quarter.
The Motley Fool April 20, 2005 John Reeves	Winning Ugly With Value If you can keep your head when all about you are losing theirs, and even purchase when others are selling, like this example of Proctor and Gamble, you may find success in value investing.